Get started
Author

Benjamin Eades

Observed names: B. Eades, B.M., Eades, Benjamin M Eades, Benjamin M. Eades, Benjamin Mark Eades, Benjamin R. Eades
ORCID: 0000-0002-4150-7786
Observed ORCID: 0000-0002-4150-7786
OpenAlex ID: A5064758797
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
2020 · James R. Berenson, Jennifer To, et al. · Clinical Cancer Research · 37
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients
2011 · James R. Berenson, Ori Yellin, et al. · British Journal of Haematology · 31
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well‐tolerated frontline regimen
2009 · James R. Berenson, Ori Yellin, et al. · European Journal Of Haematology · 27
A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma
2010 · Gabriel N. Waterman, Ori Yellin, et al. · Annals of Hematology · 19
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib
2016 · Ariana Berenson, Suzie Vardanyan, et al. · Annals of Hematology · 17
Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study
2021 · Bernard Regidor, Marissa-Skye Goldwater, et al. · Annals of Hematology · 13
Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma
2021 · Sean Bujarski, Marissa‐Skye Goldwater, et al. · European Journal Of Haematology · 12
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma
2022 · James R. Berenson, Daisy Martinez, et al. · British Journal of Haematology · 11
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients
2022 · James R. Berenson, Clara Kim, et al. · Hematological Oncology · 10
Use of serum B‐cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone
2022 · Sean Bujarski, Christine Sutanto, et al. · Hematological Oncology · 9
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients
2023 · Scott Jew, Sean Bujarski, et al. · Targeted Oncology · 8
A phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory disease
2009 · J. R. Berenson, O. Yellin, et al. · Journal of Clinical Oncology · 8
Efficacy of Topical Use Crisaborole 2% Ointment for Treatment of Necrobiotic Xanthogranuloma Associated With Multiple Myeloma
2020 · Chace Henning, Sydney Meyers, et al. · Clinical Lymphoma Myeloma & Leukemia · 7
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen
2022 · David Daniely, Eli Forouzan, et al. · Experimental Hematology · 6
PDF
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic
2016 · Ariana Berenson, Suzie Vardanyan, et al. · Annals of Hematology · 6
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen
2022 · Jonathan Afari, Tanya M. Spektor, et al. · Experimental Hematology · 5
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma
2021 · David Yashar, Tanya M. Spektor, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 5
Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study
2018 · Zachary Gross, Ashkon Rahbari, et al. · European Journal Of Haematology · 5
Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study
2020 · Bernard Regidor, Regina Swift, et al. · Annals of Hematology · 4
A phase 1 trial of ruxolitinib, lenalidomide, and methylprednisolone for relapsed/refractory multiple myeloma patients.
2018 · James R. Berenson, Jennifer To, et al. · Journal of Clinical Oncology · 4
Serum B‐Cell Maturation Antigen as a Biomarker for Predicting Outcomes and Monitoring Patients With Waldenström Macroglobulinemia
2025 · Marissa‐Skye Goldwater, Jonathan Moore, et al. · European Journal Of Haematology · 3
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
2024 · James R. Berenson, Andrea Limon, et al. · Targeted Oncology · 3
Removal of a Silicone Gel Breast Implant in a Multiple Myeloma Patient Improved Disease Status: A Case Report
2020 · Chace Henning, James Wang, et al. · Case Reports in Oncology · 3
Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma
2022 · James R. Berenson, Daisy Martinez, et al. · Blood · 2
Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
2020 · James R. Berenson, Noemi Silagan, et al. · Blood · 2
Works count: 41
Citation count: 270
H-index: 9
I10-index: 9
Year
Topic
Type